Literature DB >> 30324795

Genetic determinants of glucose levels in pregnancy: genetic risk scores analysis and GWAS in the Norwegian STORK cohort.

Gunn-Helen Moen1,2, Marissa LeBlanc3, Christine Sommer1, Rashmi B Prasad4, Tove Lekva5, Kjersti R Normann2,6, Elisabeth Qvigstad1, Leif Groop4,7, Kåre I Birkeland2,8, David M Evans9,10, Kathrine F Frøslie11.   

Abstract

Objective Hyperglycaemia during pregnancy increases the risk of adverse health outcomes in mother and child, but the genetic aetiology is scarcely studied. Our aims were to (1) assess the overlapping genetic aetiology between the pregnant and non-pregnant population and (2) assess the importance of genome-wide polygenic contributions to glucose traits during pregnancy, by exploring whether genetic risk scores (GRSs) for fasting glucose (FG), 2-h glucose (2hG), type 2 diabetes (T2D) and BMI in non-pregnant individuals were associated with glucose measures in pregnant women. Methods We genotyped 529 Norwegian pregnant women and constructed GRS from known genome-wide significant variants and SNPs weakly associated (p > 5 × 10-8) with FG, 2hG, BMI and T2D from external genome-wide association studies (GWAS) and examined the association between these scores and glucose measures at gestational weeks 14-16 and 30-32. We also performed GWAS of FG, 2hG and shape information from the glucose curve during an oral glucose tolerance test (OGTT). Results GRSFG explained similar variance during pregnancy as in the non-pregnant population (~5%). GRSBMI and GRST2D explained up to 1.3% of the variation in the glucose traits in pregnancy. If we included variants more weakly associated with these traits, GRS2hG and GRST2D explained up to 2.4% of the variation in the glucose traits in pregnancy, highlighting the importance of polygenic contributions. Conclusions Our results suggest overlap in the genetic aetiology of FG in pregnant and non-pregnant individuals. This was less apparent with 2hG, suggesting potential differences in postprandial glucose metabolism inside and outside of pregnancy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30324795     DOI: 10.1530/EJE-18-0478

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Elucidating the role of maternal environmental exposures on offspring health and disease using two-sample Mendelian randomization.

Authors:  David M Evans; Gunn-Helen Moen; Liang-Dar Hwang; Debbie A Lawlor; Nicole M Warrington
Journal:  Int J Epidemiol       Date:  2019-06-01       Impact factor: 7.196

2.  Defining Heterogeneity Among Women With Gestational Diabetes Mellitus.

Authors:  Camille E Powe; Marie-France Hivert; Miriam S Udler
Journal:  Diabetes       Date:  2020-08-25       Impact factor: 9.461

3.  Cohort profile: Epigenetics in Pregnancy (EPIPREG) - population-based sample of European and South Asian pregnant women with epigenome-wide DNA methylation (850k) in peripheral blood leukocytes.

Authors:  Nicolas Fragoso-Bargas; Julia O Opsahl; Nadezhda Kiryushchenko; Yvonne Böttcher; Sindre Lee-Ødegård; Elisabeth Qvigstad; Kåre Rønn Richardsen; Christin W Waage; Line Sletner; Anne Karen Jenum; Rashmi B Prasad; Leif C Groop; Gunn-Helen Moen; Kåre I Birkeland; Christine Sommer
Journal:  PLoS One       Date:  2021-08-13       Impact factor: 3.240

4.  The Association of Gene Variants in the Vitamin D Metabolic Pathway and Its Interaction with Vitamin D on Gestational Diabetes Mellitus: A Prospective Cohort Study.

Authors:  Minjia Mo; Bule Shao; Xing Xin; Wenliang Luo; Shuting Si; Wen Jiang; Shuojia Wang; Yu Shen; Jinhua Wu; Yunxian Yu
Journal:  Nutrients       Date:  2021-11-24       Impact factor: 5.717

5.  Genetic Loci and Physiologic Pathways Involved in Gestational Diabetes Mellitus Implicated Through Clustering.

Authors:  Camille E Powe; Miriam S Udler; Sarah Hsu; Catherine Allard; Alan Kuang; Alisa K Manning; Patrice Perron; Luigi Bouchard; William L Lowe; Denise Scholtens; Jose C Florez; Marie-France Hivert
Journal:  Diabetes       Date:  2020-10-13       Impact factor: 9.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.